 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Patients with advanced ovarian cancer should not be treated with immune checkpoint inhibitors!

J Clin Oncol: Patients with advanced ovarian cancer should not be treated with immune checkpoint inhibitors!

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

anti cancer drugs

zinc cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Epithelial ovarian cancer (OC) is the leading cause of cancer-related deaths in women worldwide: It is estimated that in 2018, the number of deaths due to OC worldwide was close to 185,000 .

The number of ovarian cancer deaths worldwide due to OC in 2018 is close to 185,000

This study aims to evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to the platinum-based combination with bevacizumab for newly diagnosed stage III-IV Efficacy of ovarian cancer .

To evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to newly diagnosed stage III-IV ovarian cancer in the platinum-based combination with bevacizumab Efficacy

This is a multicenter, placebo-controlled, randomized, double-blind phase III trial that recruited newly diagnosed patients with stage III-IV ovarian cancer who had undergone primary tumor cytoreduction or planned to undergo Neoadjuvant chemotherapy and interval surgery.

PFS and OS in the intention-to-treat population and PD-L1 positive population

From March 8, 2017 to March 26, 2019, a total of 1301 patients were recruited.

In the intention-to-treat population, the median progression-free survival of the atuzumab group and the placebo group was 19.

PFS in PD-L1 positive subgroup

Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and placebo group was 20.

Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and the placebo group were 20.

In summary, the current analysis results of the study do not support the use of immune checkpoint inhibitors for newly diagnosed ovarian cancer patients .

Newly diagnosed ovarian cancer using immune checkpoint inhibitor use of newly diagnosed ovarian cancer immune checkpoint inhibitors of immune

Original source:

Kathleen N.

org/doi/full/10.
1200/JCO.
21.
00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050 / GOG 3015 / ENGOT-OV39) in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.